Reports On Company: Krishna Institute Of Medical Sciences
| KIMS is steadily building its empire by conquering and ruling. Buy for target price of Rs 1682 (18% upside) | |
| Company: | KIMS, Krishna Institute Of Medical Sciences |
| Brokerage: | SMIFS |
| Date of report: | January 23, 2023 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 18% |
| Summary: | Currently, the stock is trading at comforting valuation on FY25E EV/EBITDA of 15x. We value the stock at 20x (in line with its historical average) due to capacity and geographical expansion, improved margins and robust revenue growth, thereby, arrive at target price of Rs 1,682 per share which offers upside of 18% from current valuations. Therefore, we assign BUY rating on the stock. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | |